Zobrazeno 1 - 10
of 2 229
pro vyhledávání: '"anti-egfr"'
Publikováno v:
Orphanet Journal of Rare Diseases, Vol 19, Iss 1, Pp 1-12 (2024)
Abstract Background Invasive cutaneous squamous cell carcinomas (cSCC) are a leading cause of death in recessive dystrophic epidermolysis bullosa (RDEB), a rare blistering genodermatosis. Outcomes of RDEB-cSCC therapies have primarily been described
Externí odkaz:
https://doaj.org/article/64f39d56a71f4cad83d2160f67236646
Autor:
Kozo Kataoka, Takeshi Yamada, Manabu Shiozawa, Naoto Takase, Kazuma Ito, Kentaro Yamazaki, Jun Watanabe, Toshihiro Kudo, Takeshi Suto, Toshihiko Matsumoto, Kohei Murata, Yusuke Suwa, Shogen Boku, Hisateru Yasui, Nobuhisa Matsuhashi, Atsuyuki Maeda, Kiichi Sugimoto, Yusuke Matsumoto, Mitsuru Yokota, Johannes Fredebohm, Keita Mori, Masataka Ikeda
Publikováno v:
Journal of the Anus, Rectum and Colon, Vol 8, Iss 2, Pp 132-136 (2024)
Background: Spatial and temporal heterogeneities of RAS and other molecular genes should be considered in the treatment of metastatic colorectal cancer (mCRC) treated with anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs); acq
Externí odkaz:
https://doaj.org/article/3c42bc614e4e45ca97f85e629c86cea8
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Pharmacological Research, Vol 206, Iss , Pp 107304- (2024)
Over the last decade, epidermal growth factor receptor (EGFR)-targeted therapies have transformed the treatment landscape for patients with advanced solid tumors. Despite these advances, resistance to anti-EGFR therapies is still a significant clinic
Externí odkaz:
https://doaj.org/article/f602e200b1e64c9eb7d38521b5d08eb2
Autor:
Masatsune Shibutani, Hideki Tanda, Tatsunari Fukuoka, Hiroaki Kasashima, Shinichiro Kashiwagi, Kiyoshi Maeda
Publikováno v:
Case Reports in Oncology, Vol 17, Iss 1, Pp 511-516 (2024)
Introduction: Reexposure to anti-EGFR antibodies, such as a reintroduction or rechallenge with anti-EGFR antibodies, has attracted much attention in the field of metastatic colorectal cancer. A reintroduction of anti-EGFR antibodies often shows good
Externí odkaz:
https://doaj.org/article/a91cc0cf75f146e587d8e377595aa892
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
Emergence of acquired resistance limits the efficacy of the anti-EGFR therapies cetuximab and panitumumab in metastatic colorectal cancer. In the last decade, preclinical and clinical cohort studies have uncovered genomic alterations that confer a se
Externí odkaz:
https://doaj.org/article/c28e85a75e614631a6dc3789a815a36c
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-27 (2023)
Abstract Background RAS mutations affect prognosis in patients with metastatic colorectal cancer (mCRC) and have been identified as strong negative predictive markers for anti-epidermal growth factor receptor monoclonal antibody (anti-EGFR mAb) thera
Externí odkaz:
https://doaj.org/article/97cc2c35ef014513b1e5fa3aa849f062
Autor:
Yang Wang, Xiangyuan Li, Tongmin Huang, Dongying Wang, Yujing He, Mengfei Wei, Yujie Chen, Matao Zheng, Yetan Shi, Jianjian Zhang
Publikováno v:
World Journal of Surgical Oncology, Vol 21, Iss 1, Pp 1-13 (2023)
Abstract Background Adding anti-epidermal growth factor receptor (anti-EGFR) target agents to conversion therapy may improve the resection rates and survival of patients with potentially resectable metastatic colorectal cancer (mCRC). This study aims
Externí odkaz:
https://doaj.org/article/40957d65644b483c902566ce98fcad4d
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
Purpose:To investigate the survival outcomes and toxicities associated with the addition of nimotuzumab to concurrent chemoradiotherapy (CCRT) in locally advanced nasopharyngeal carcinoma (LANPC) patients who received induction chemotherapy (IC).Meth
Externí odkaz:
https://doaj.org/article/8e51f98ee8f0419281c2b7881e9e9310
Autor:
Marco Maria Germani, Guglielmo Vetere, Mirella Giordano, Paolo Ciracì, Iolanda Capone, Elena Tamborini, Elena Conca, Adele Busico, Filippo Pietrantonio, Vittoria Matilde Piva, Alessandra Boccaccino, Francesca Simionato, Martina Bortolot, Paolo Manca, Sara Lonardi, Veronica Conca, Beatrice Borelli, Martina Carullo, Marzia Del Re, Gabriella Fontanini, Daniele Rossini, Chiara Cremolini
Publikováno v:
Frontiers in Oncology, Vol 13 (2024)
BackgroundRetreatment with anti-EGFR monoclonal antibodies is a promising strategy in patients with RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC) who achieved benefit from previous anti-EGFR exposure upon exclusion of mutations in RAS/B
Externí odkaz:
https://doaj.org/article/119b59c1dc1d407698a8eee5621f82dc